[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"ReCor Medical, Inc.\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":91},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,3,0,[8,43,72],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":22,"studyType":23,"phases":4,"briefSummary":24,"conditions":25,"keywords":27,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":31,"lastUpdatePostDateStruct":32,"startDateStruct":35,"completionDateStruct":37,"leadSponsor":39,"locationsCount":42},"100441386","the-global-paradise-system-registry-100441386",false,"NCT05027685","The \"Global Paradise System\" Registry","The \"Global Paradise® System\" Registry","GPSRegistry","Inclusion Criteria:\n\n* Appropriately signed and dated informed consent\n* Age ≥18 at time of consent\n* Patient candidate for renal denervation with the Paradise System based on physician's assessment OR Patient treated with the Paradise Ultrasound Renal Denervation System within the 6 months prior to consent\n\nExclusion Criteria:\n\nPatients who meet any of the contraindications listed in the Instructions for Use will be excluded.\n\nThe contraindications are:\n\n* Stented renal artery\n* Less than 18 years of age\n* Pregnant\n* Known allergy to contrast medium\n* Renal arteries diameter \\\u003C 3 mm and \\> 8 mm\n* Renal artery with Fibromuscular (FMD) disease\n* Renal artery aneurysm\n* Renal artery stenosis of any origin \\>30%\n* Iliac\u002Ffemoral artery stenosis precluding insertion of the Paradise catheter","ALL","18 Years",{"count":20,"type":21},3000,"ESTIMATED","5 Years","OBSERVATIONAL","The GPS Registry is a multi-centre, single-arm, non-interventional (observational) registry. In addition to collecting data from patients treated as per standard clinical practice, the Registry will also regularly collect telemetric Home Blood Pressure (HBP) measurements and Patient Reported Outcome (PRO) data via a standardized quality of life questionnaire. The objective of the GPS Registry is to document the long-term safety and effectiveness of the commercially available Paradise Ultrasound Renal Denervation System when used per its labelling in patients deemed to be candidates for RDN as per physician's assessment.",[26],"Hypertension",[26,28,29],"Blood pressure","Renal Denervation","RECRUITING","2026-06-02",{"date":33,"type":34},"2026-06-04","ACTUAL",{"date":36,"type":34},"2022-01-13",{"date":38,"type":21},"2031-12-31",{"name":40,"class":41},"ReCor Medical, Inc.","INDUSTRY",55,{"id":44,"slug":45,"hasResults":11,"nctId":46,"briefTitle":47,"officialTitle":48,"acronym":49,"eligibilityCriteria":50,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":51,"targetDuration":22,"studyType":23,"phases":4,"briefSummary":53,"conditions":54,"keywords":57,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":63,"lastUpdatePostDateStruct":64,"startDateStruct":66,"completionDateStruct":68,"leadSponsor":70,"locationsCount":71},"100538934","global-paradise-system-us-post-approval-study-100538934","NCT06297291","Global Paradise System US Post Approval Study","The Global Paradise® System US Post Approval Study (US GPS)","US GPS","Inclusion Criteria:\n\n* Signed and dated study informed consent\n* Documented history of hypertension\n* Documented history of prior or current antihypertensive medication(s)\n* Mean seated office systolic BP at screening ≥ 140 mmHg\n* Mean pre-procedure home systolic BP of ≥ 135 mmHg\n* Estimated glomerular filtration rate (eGFR) of ≥30 mL\u002Fmin\u002Fm2\n\nRADIANCE CAP patients must provide signed and dated informed consent for inclusion in long-term follow-up. No other criteria are required for inclusion.\n\nExclusion Criteria:\n\nPatients who meet the following will be excluded from participation:\n\n* Patient lacks appropriate renal anatomy for any treatment with the Paradise Catheter\n* Patient under the age of 18 years old at the time of consent\n* Patient is pregnant\n* Patients with transplanted kidney\n* Presence of abnormal kidney (or secreting adrenal) tumors\n\nTo confirm eligibility for treatment with the Paradise System, the following contraindications listed in the IFU may be determined at the time of procedure prior to treatment:\n\n* Renal arteries with diameter \\\u003C 3mm and \\> 8mm\n* Renal artery with fibromuscular dysplasia (FMD)\n* Stented renal artery\n* Renal artery aneurysm\n* Renal artery diameter stenosis \\>30%\n* Iliac\u002Ffemoral artery stenosis precluding insertion of the Paradise Catheter",{"count":52,"type":21},1000,"The objective of the Global Paradise® System US Post Approval Study (US GPS) is to evaluate the real-world use of the Paradise Ultrasound Renal Denervation System indicated for patients who are unable to lower their blood pressure with lifestyle changes and medication. This system is comprised of a catheter, cable, balloon, and generator and has received FDA approval in the United States. Information collected in this study will be analyzed to better understand the long-term safety and effectiveness of treatment with the Paradise System for patients with high blood pressure.",[26,55,56],"Cardiovascular Diseases","Vascular Diseases",[58,59,60,61,29,62],"Blood Pressure","Uncontrolled Hypertension","Essential Hypertension","Resistant Hypertension","Ultrasound Renal Denervation","2026-05-01",{"date":65,"type":34},"2026-05-07",{"date":67,"type":34},"2024-06-28",{"date":69,"type":21},"2031-07",{"name":40,"class":41},39,{"id":73,"slug":74,"hasResults":11,"nctId":75,"briefTitle":76,"officialTitle":77,"acronym":4,"eligibilityCriteria":78,"healthyVolunteers":11,"sex":17,"minAge":79,"maxAge":4,"enrollmentInfo":80,"targetDuration":4,"studyType":23,"phases":4,"briefSummary":81,"conditions":82,"keywords":4,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":83,"lastUpdatePostDateStruct":84,"startDateStruct":86,"completionDateStruct":88,"leadSponsor":89,"locationsCount":90},"100610759","the-radiance-ced-study-100610759","NCT07231757","The RADIANCE CED Study","The Recor Paradise System™ Hypertension Coverage With Evidence Development Study","Common Inclusion Criteria:\n\n* Adults aged ≥65 years with uncontrolled hypertension\n* Stable regimen of blood pressure-lowering medication\n\nCommon Exclusion Criteria:\n\n* Hypertension due to secondary causes\n* Prior renal denervation treatment\n* Pregnancy\n* End-stage renal disease, dialysis, or kidney transplant","65 Years",{"count":52,"type":21},"The RADIANCE CED study is a prospective observational study designed to evaluate the long-term effectiveness of ultrasound renal denervation in lowering blood pressure among patients with uncontrolled hypertension. Data will be collected from electronic health records (EHRs) of Medicare-eligible patients to support generalizability of outcomes to the broader Medicare population. Individual hospital enrollment is not required for this study and IRB exemption has been received by sponsor.",[26,55,56],"2026-01-07",{"date":85,"type":34},"2026-01-09",{"date":87,"type":34},"2025-11-21",{"date":38,"type":21},{"name":40,"class":41},1,""]